-
1
-
-
33847076849
-
Chromatin modifications and their function
-
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
-
(2007)
Cell
, vol.128
, pp. 693-705
-
-
Kouzarides, T.1
-
2
-
-
75749101495
-
Chromatin remodelling during development
-
Ho, L., & Crabtree, G. R. Chromatin remodelling during development. Nature 463, 474-484 (2010).
-
(2010)
Nature
, vol.463
, pp. 474-484
-
-
Ho, L.1
Crabtree, G.R.2
-
3
-
-
84871901456
-
Objective assessment of cancer genes for drug discovery
-
Patel, M. N., Halling-Brown, M. D., Tym, J. E., Workman, P., & Al Lazikani, B. Objective assessment of cancer genes for drug discovery. Nat. Rev. Drug Discov. 12, 35-50 (2013).
-
(2013)
Nat. Rev. Drug Discov.
, vol.12
, pp. 35-50
-
-
Patel, M.N.1
Halling-Brown, M.D.2
Tym, J.E.3
Workman, P.4
Al Lazikani, B.5
-
4
-
-
1542515338
-
A census of human cancer genes
-
Futreal, P. A., et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 177-183
-
-
Futreal, P.A.1
-
5
-
-
84863393263
-
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
-
Patel, J. P., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 1079-1089
-
-
Patel, J.P.1
-
6
-
-
84866378702
-
The role of mutations in epigenetic regulators in myeloid malignancies
-
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599-612 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 599-612
-
-
Shih, A.H.1
Abdel-Wahab, O.2
Patel, J.P.3
Levine, R.L.4
-
7
-
-
84890717859
-
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
-
Shi, J., et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27, 2648-2662 (2013).
-
(2013)
Genes Dev.
, vol.27
, pp. 2648-2662
-
-
Shi, J.1
-
8
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan, H., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 765-773
-
-
Yan, H.1
-
9
-
-
55949136562
-
Roles of the EZH2 histone methyltransferase in cancer epigenetics
-
Simon, J. A., & Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29 (2008).
-
(2008)
Mutat. Res.
, vol.647
, pp. 21-29
-
-
Simon, J.A.1
Lange, C.A.2
-
10
-
-
75749124332
-
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin
-
Morin, R. D., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
-
(2010)
Nat. Genet.
, vol.42
, pp. 181-185
-
-
Morin, R.D.1
-
11
-
-
67349203626
-
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
-
van Haaften, G., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
-
(2009)
Nat. Genet.
, vol.41
, pp. 521-523
-
-
Van Haaften, G.1
-
12
-
-
79959653996
-
SWI/SNF nucleosome remodellers and cancer
-
Wilson, B. G., & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011).
-
(2011)
Nat. Rev. Cancer
, vol.11
, pp. 481-492
-
-
Wilson, B.G.1
Roberts, C.W.2
-
13
-
-
84878745222
-
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
-
Kadoch, C., et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601 (2013).
-
(2013)
Nat. Genet.
, vol.45
, pp. 592-601
-
-
Kadoch, C.1
-
14
-
-
2642647094
-
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
-
Versteege, I., et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206 (1998).
-
(1998)
Nature
, vol.394
, pp. 203-206
-
-
Versteege, I.1
-
15
-
-
77957731999
-
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma
-
Jones, S., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
-
(2010)
Science
, vol.330
, pp. 228-231
-
-
Jones, S.1
-
16
-
-
77957946398
-
ARID1A mutations in endometriosis-Associated ovarian carcinomas
-
Wiegand, K. C., et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1532-1543
-
-
Wiegand, K.C.1
-
17
-
-
84863621527
-
Cancer epigenetics: From mechanism to therapy
-
Dawson, M. A., & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012).
-
(2012)
Cell
, vol.150
, pp. 12-27
-
-
Dawson, M.A.1
Kouzarides, T.2
-
18
-
-
84875745673
-
Interplay between the cancer genome and epigenome
-
Shen, H., & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38-55 (2013).
-
(2013)
Cell
, vol.153
, pp. 38-55
-
-
Shen, H.1
Laird, P.W.2
-
19
-
-
50249186849
-
Inhibition of transcription factors with small organic molecules
-
Berg, T. Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 12, 464-471 (2008).
-
(2008)
Curr. Opin. Chem. Biol.
, vol.12
, pp. 464-471
-
-
Berg, T.1
-
20
-
-
0036782706
-
Transcription factors as targets for cancer therapy
-
Darnell, J. E. Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 740-749
-
-
Darnell, J.E.1
-
21
-
-
77952545553
-
A complex task? Direct modulation of transcription factors with small molecules
-
Koehler, A. N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331-340 (2010).
-
(2010)
Curr. Opin. Chem. Biol.
, vol.14
, pp. 331-340
-
-
Koehler, A.N.1
-
22
-
-
84932634729
-
Phthalimide conjugation as a strategy for in vivo target protein degradation
-
Winter, G. E., et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
-
(2015)
Science
, vol.348
, pp. 1376-1381
-
-
Winter, G.E.1
-
23
-
-
77249142404
-
The art of the chemical probe
-
Frye, S. V. The art of the chemical probe. Nat. Chem. Biol. 6, 159-161 (2010).
-
(2010)
Nat. Chem. Biol.
, vol.6
, pp. 159-161
-
-
Frye, S.V.1
-
24
-
-
85050578395
-
Inhibitors of emerging epigenetic targets for cancer therapy: A patent review 2010-2014
-
Tanaka, M., Roberts, J. M., Qi, J., & Bradner, J. E. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharm. Pat. Anal. 4, 261-284 (2015).
-
(2015)
Pharm. Pat. Anal.
, vol.4
, pp. 261-284
-
-
Tanaka, M.1
Roberts, J.M.2
Qi, J.3
Bradner, J.E.4
-
25
-
-
69949148388
-
Protein methyltransferases as a target class for drug discovery
-
Copeland, R. A., Solomon, M. E., & Richon, V. M. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8, 724-732 (2009).
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 724-732
-
-
Copeland, R.A.1
Solomon, M.E.2
Richon, V.M.3
-
26
-
-
59349115177
-
Chemical mechanisms of histone lysine and arginine modifications
-
Smith, B. C., & Denu, J. M. Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta 1789, 45-57 (2009).
-
(2009)
Biochim. Biophys. Acta
, vol.1789
, pp. 45-57
-
-
Smith, B.C.1
Denu, J.M.2
-
27
-
-
84858636152
-
Current chemical biology approaches to interrogate protein methyltransferases
-
Luo, M. Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem. Biol. 7, 443-463 (2012).
-
(2012)
ACS Chem. Biol.
, vol.7
, pp. 443-463
-
-
Luo, M.1
-
28
-
-
17444375685
-
HDOT1L links histone methylation to leukemogenesis
-
Okada, Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005).
-
(2005)
Cell
, vol.121
, pp. 167-178
-
-
Okada, Y.1
-
29
-
-
0018122025
-
The antifungal antibiotic sinefungin as a very active inhibitor of methyltransferases and of the transformation of chick embryo fibroblasts by Rous sarcoma virus
-
Vedel, M., Lawrence, F., Robert-Gero, M., & Lederer, E. The antifungal antibiotic sinefungin as a very active inhibitor of methyltransferases and of the transformation of chick embryo fibroblasts by Rous sarcoma virus. Biochem. Biophys. Res. Commun. 85, 371-376 (1978).
-
(1978)
Biochem. Biophys. Res. Commun.
, vol.85
, pp. 371-376
-
-
Vedel, M.1
Lawrence, F.2
Robert-Gero, M.3
Lederer, E.4
-
30
-
-
30644474460
-
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)
-
Greiner, D., Bonaldi, T., Eskeland, R., Roemer, E., & Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3 9. Nat. Chem. Biol. 1, 143-145 (2005).
-
(2005)
Nat. Chem. Biol. 1
, vol.3
, Issue.9
, pp. 143-145
-
-
Greiner, D.1
Bonaldi, T.2
Eskeland, R.3
Roemer, E.4
Imhof, A.5
-
31
-
-
84874041667
-
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases
-
Cherblanc, F. L., Chapman, K. L., Brown, R., & Fuchter, M. J. Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat. Chem. Biol. 9, 136-137 (2013).
-
(2013)
Nat. Chem. Biol.
, vol.9
, pp. 136-137
-
-
Cherblanc, F.L.1
Chapman, K.L.2
Brown, R.3
Fuchter, M.J.4
-
32
-
-
0021194198
-
Effects of adenosine dialdehyde on S adenosylhomocysteine hydrolase and S adenosylmethionine-dependent transmethylations in mouse L929 cells
-
Bartel, R. L., & Borchardt, R. T. Effects of adenosine dialdehyde on S adenosylhomocysteine hydrolase and S adenosylmethionine-dependent transmethylations in mouse L929 cells. Mol. Pharmacol. 25, 418-424 (1984).
-
(1984)
Mol. Pharmacol.
, vol.25
, pp. 418-424
-
-
Bartel, R.L.1
Borchardt, R.T.2
-
33
-
-
0025975888
-
4, 5. Unsaturated 5. Halogenated nucleosides. Mechanism-based and competitive inhibitors of S adenosyl-l homocysteine hydrolase
-
Jarvi, E. T., et al. 4, 5. unsaturated 5. halogenated nucleosides. Mechanism-based and competitive inhibitors of S adenosyl-l homocysteine hydrolase. J. Med. Chem. 34, 647-656 (1991).
-
(1991)
J. Med. Chem.
, vol.34
, pp. 647-656
-
-
Jarvi, E.T.1
-
34
-
-
34248645046
-
-
eds Clarke, S. G., & Tamanoi, F. Elsevier
-
Clarke, S. G. in The Enzymes: Protein Methyltransferases Vol. 24 (eds Clarke, S. G., & Tamanoi, F.) 467-493 (Elsevier, 2006).
-
(2006)
The Enzymes: Protein Methyltransferases
, vol.24
, pp. 467-493
-
-
Clarke, S.G.1
-
35
-
-
67649371461
-
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
-
Miranda, T. B., et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 1579-1588
-
-
Miranda, T.B.1
-
36
-
-
0027131996
-
Z-4' 5' didehydro 5' Deoxy 5' fluoroadenosine (MDL 28 842), an irreversible inhibitor of S adenosylhomocysteine hydrolase, suppresses proliferation of cultured keratinocytes and squamous carcinoma cell lines
-
Paller, A. S., Arnsmeier, S. L., Clark, S. H., & Mirkin, B. L. Z-4?, 5? didehydro 5? deoxy 5? fluoroadenosine (MDL 28, 842), an irreversible inhibitor of S adenosylhomocysteine hydrolase, suppresses proliferation of cultured keratinocytes and squamous carcinoma cell lines. Cancer Res. 53, 6058-6060 (1993).
-
(1993)
Cancer Res.
, vol.53
, pp. 6058-6060
-
-
Paller, A.S.1
Arnsmeier, S.L.2
Clark, S.H.3
Mirkin, B.L.4
-
37
-
-
34247625135
-
Pharmacologic disruption of Polycomb-repressive complex 2 mediated gene repression selectively induces apoptosis in cancer cells
-
Tan, J., et al. Pharmacologic disruption of Polycomb-repressive complex 2 mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
-
(2007)
Genes Dev.
, vol.21
, pp. 1050-1063
-
-
Tan, J.1
-
38
-
-
0037099413
-
G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis
-
Tachibana, M., et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16, 1779-1791 (2002).
-
(2002)
Genes Dev.
, vol.16
, pp. 1779-1791
-
-
Tachibana, M.1
-
39
-
-
33645751058
-
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state
-
McGarvey, K. M., et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66, 3541-3549 (2006).
-
(2006)
Cancer Res.
, vol.66
, pp. 3541-3549
-
-
McGarvey, K.M.1
-
40
-
-
44249128891
-
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells
-
Kondo, Y., et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 3, e2037 (2008).
-
(2008)
PLoS ONE
, vol.3
, pp. e2037
-
-
Kondo, Y.1
-
41
-
-
84889684498
-
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation
-
Ding, J., et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab. 18, 896-907 (2013).
-
(2013)
Cell Metab.
, vol.18
, pp. 896-907
-
-
Ding, J.1
-
42
-
-
33846783261
-
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
-
Kubicek, S., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481 (2007).
-
(2007)
Mol. Cell
, vol.25
, pp. 473-481
-
-
Kubicek, S.1
-
43
-
-
62049083789
-
Structural basis for G9a like protein lysine methyltransferase inhibition by BIX 01294
-
Chang, Y., et al. Structural basis for G9a like protein lysine methyltransferase inhibition by BIX 01294. Nat. Struct. Mol. Biol. 16, 312-317 (2009).
-
(2009)
Nat. Struct. Mol. Biol.
, vol.16
, pp. 312-317
-
-
Chang, Y.1
-
44
-
-
73249124141
-
Discovery of a 2, 4 diamino 7 aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a
-
Liu, F., et al. Discovery of a 2, 4 diamino 7 aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52, 7950-7953 (2009).
-
(2009)
J. Med. Chem.
, vol.52
, pp. 7950-7953
-
-
Liu, F.1
-
45
-
-
77955363182
-
Protein lysine methyltransferase G9a inhibitors: Design, syn thesis, and structure activity relationships of 2, 4 diamino 7 aminoalkoxy-quinazolines
-
Liu, F., et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2, 4 diamino 7 aminoalkoxy-quinazolines. J. Med. Chem. 53, 5844-5857 (2010).
-
(2010)
J. Med. Chem.
, vol.53
, pp. 5844-5857
-
-
Liu, F.1
-
46
-
-
80052375547
-
Optimization of cellular activity of G9a inhibitors 7 aminoalkoxy-quinazolines
-
Liu, F., et al. Optimization of cellular activity of G9a inhibitors 7 aminoalkoxy-quinazolines. J. Med. Chem. 54, 6139-6150 (2011).
-
(2011)
J. Med. Chem.
, vol.54
, pp. 6139-6150
-
-
Liu, F.1
-
47
-
-
79960493567
-
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
-
Vedadi, M., et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7, 566-574 (2011).
-
(2011)
Nat. Chem. Biol.
, vol.7
, pp. 566-574
-
-
Vedadi, M.1
-
48
-
-
84887923349
-
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP
-
Liu, F., et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J. Med. Chem. 56, 8931-8942 (2013).
-
(2013)
J. Med. Chem.
, vol.56
, pp. 8931-8942
-
-
Liu, F.1
-
49
-
-
84893972052
-
The methyltransferase G9a regulates HoxA9 dependent transcription in AML
-
Lehnertz, B., et al. The methyltransferase G9a regulates HoxA9 dependent transcription in AML. Genes Dev. 28, 317-327 (2014).
-
(2014)
Genes Dev.
, vol.28
, pp. 317-327
-
-
Lehnertz, B.1
-
50
-
-
84869162797
-
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment
-
Chen, X., et al. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev. 26, 2499-2511 (2012).
-
(2012)
Genes Dev.
, vol.26
, pp. 2499-2511
-
-
Chen, X.1
-
51
-
-
84894065529
-
Discovery and development of potent and selective inhibitors of histone methyltransferase G9a
-
Sweis, R. F., et al. Discovery and development of potent and selective inhibitors of histone methyltransferase G9a. ACS Med. Chem. Lett. 5, 205-209 (2014).
-
(2014)
ACS Med. Chem. Lett.
, vol.5
, pp. 205-209
-
-
Sweis, R.F.1
-
52
-
-
84940093455
-
The histone methyltransferase inhibitor A-366 uncovers a role for G9a/GLP in the epigenetics of leukemia
-
Pappano, W. N., et al. The histone methyltransferase inhibitor A-366 uncovers a role for G9a/GLP in the epigenetics of leukemia. PLoS ONE 10, e0131716 (2015).
-
(2015)
PLoS ONE
, vol.10
, pp. e0131716
-
-
Pappano, W.N.1
-
53
-
-
84864140929
-
A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma
-
Yuan, Y., et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol. 7, 1152-1157 (2012).
-
(2012)
ACS Chem. Biol.
, vol.7
, pp. 1152-1157
-
-
Yuan, Y.1
-
54
-
-
79960044951
-
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L
-
Bernt, K. M., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011).
-
(2011)
Cancer Cell
, vol.20
, pp. 66-78
-
-
Bernt, K.M.1
-
55
-
-
84993940217
-
DOT1L as a therapeutic target for the treatment of DNMT3A mutant acute myeloid leukemia
-
Rau, R. E., et al. DOT1L as a therapeutic target for the treatment of DNMT3A mutant acute myeloid leukemia. Blood 128, 971-981 (2016).
-
(2016)
Blood
, vol.128
, pp. 971-981
-
-
Rau, R.E.1
-
56
-
-
0344837759
-
Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase
-
Min, J., Feng, Q., Li, Z., Zhang, Y., & Xu, R. M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112, 711-723 (2003).
-
(2003)
Cell
, vol.112
, pp. 711-723
-
-
Min, J.1
Feng, Q.2
Li, Z.3
Zhang, Y.4
Xu, R.M.5
-
57
-
-
79960367903
-
Chemogenetic analysis of human protein methyltransferases
-
Richon, V. M., et al. Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199-210 (2011).
-
(2011)
Chem. Biol. Drug Des.
, vol.78
, pp. 199-210
-
-
Richon, V.M.1
-
58
-
-
79960058024
-
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
-
Daigle, S. R., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
-
(2011)
Cancer Cell
, vol.20
, pp. 53-65
-
-
Daigle, S.R.1
-
59
-
-
84871737742
-
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
-
Yu, W., et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288 (2012).
-
(2012)
Nat. Commun.
, vol.3
, pp. 1288
-
-
Yu, W.1
-
60
-
-
84868101932
-
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L
-
Basavapathruni, A., et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80, 971-980 (2012).
-
(2012)
Chem. Biol. Drug Des.
, vol.80
, pp. 971-980
-
-
Basavapathruni, A.1
-
61
-
-
84886864184
-
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
-
Daigle, S. R., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017-1025 (2013).
-
(2013)
Blood
, vol.122
, pp. 1017-1025
-
-
Daigle, S.R.1
-
62
-
-
80055019988
-
Selective inhibitors of histone methyltransferase DOT1L: Design, syn
-
thesis, and crystallographic studies
-
Yao, Y., et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J. Am. Chem. Soc. 133, 16746-16749 (2011).
-
(2011)
J. Am. Chem. Soc.
, vol.133
, pp. 16746-16749
-
-
Yao, Y.1
-
63
-
-
84875217644
-
Bromo-deaza-SAH: A potent and selective DOT1L inhibitor
-
Yu, W., et al. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg. Med. Chem. 21, 1787-1794 (2013).
-
(2013)
Bioorg. Med. Chem.
, vol.21
, pp. 1787-1794
-
-
Yu, W.1
-
64
-
-
84877312453
-
Activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L
-
thesis
-
Deng, L., et al. Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. MedChemComm. 4, 822-826 (2013).
-
(2013)
MedChemComm.
, vol.4
, pp. 822-826
-
-
Deng, L.1
Syn, E.2
-
65
-
-
84925620054
-
Structure-guided DOT1L probe optimization by label-free ligand displacement
-
Yi, J. S., et al. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem. Biol. 10, 667-674 (2015).
-
(2015)
ACS Chem. Biol.
, vol.10
, pp. 667-674
-
-
Yi, J.S.1
-
66
-
-
84872531591
-
High-Affinity small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction
-
Karatas, H., et al. High-Affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J. Am. Chem. Soc.135, 669-682 (2013).
-
(2013)
J. Am. Chem. Soc.135
, pp. 669-682
-
-
Karatas, H.1
-
67
-
-
84892841527
-
Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia
-
Cao, F., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53, 247-261 (2014).
-
(2014)
Mol. Cell
, vol.53
, pp. 247-261
-
-
Cao, F.1
-
68
-
-
84857195696
-
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
-
Grembecka, J., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277-284 (2012).
-
(2012)
Nat. Chem. Biol.
, vol.8
, pp. 277-284
-
-
Grembecka, J.1
-
69
-
-
84896871890
-
High-Affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction
-
He, S., et al. High-Affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J. Med. Chem. 57, 1543-1556 (2014).
-
(2014)
J. Med. Chem.
, vol.57
, pp. 1543-1556
-
-
He, S.1
-
70
-
-
84870573126
-
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2 activating mutations
-
McCabe, M. T., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2 activating mutations. Nature 492, 108-112 (2012).
-
(2012)
Nature
, vol.492
, pp. 108-112
-
-
McCabe, M.T.1
-
71
-
-
84867632489
-
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
-
Knutson, S. K., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
-
(2012)
Nat. Chem. Biol.
, vol.8
, pp. 890-896
-
-
Knutson, S.K.1
-
72
-
-
84871841675
-
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
-
Qi, W., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109, 21360-21365 (2012).
-
(2012)
Proc. Natl Acad. Sci. USA
, vol.109
, pp. 21360-21365
-
-
Qi, W.1
-
73
-
-
84905572005
-
Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide
-
Riising, E. M., et al. Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide. Mol. Cell 55, 347-360 (2014).
-
(2014)
Mol. Cell
, vol.55
, pp. 347-360
-
-
Riising, E.M.1
-
74
-
-
55949132133
-
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms
-
Margueron, R., et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503-518 (2008).
-
(2008)
Mol. Cell
, vol.32
, pp. 503-518
-
-
Margueron, R.1
-
75
-
-
18644382388
-
The polycomb group protein EZH2 is involved in progression of prostate cancer
-
Varambally, S., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
-
(2002)
Nature
, vol.419
, pp. 624-629
-
-
Varambally, S.1
-
76
-
-
0141816752
-
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
-
Kleer, C. G., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 11606-11611
-
-
Kleer, C.G.1
-
77
-
-
80052029516
-
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
-
Morin, R. D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
-
(2011)
Nature
, vol.476
, pp. 298-303
-
-
Morin, R.D.1
-
78
-
-
78650062951
-
EZH2 mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
-
Velichutina, I., et al. EZH2 mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116, 5247-5255 (2010).
-
(2010)
Blood
, vol.116
, pp. 5247-5255
-
-
Velichutina, I.1
-
79
-
-
84877815031
-
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
-
Béguelin, W., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
-
(2013)
Cancer Cell
, vol.23
, pp. 677-692
-
-
Béguelin, W.1
-
80
-
-
84946227498
-
Loss of BAP1 function leads to EZH2 dependent transformation
-
LaFave, L. M., et al. Loss of BAP1 function leads to EZH2 dependent transformation. Nat. Med. 21, 1344-1349 (2015).
-
(2015)
Nat. Med.
, vol.21
, pp. 1344-1349
-
-
LaFave, L.M.1
-
81
-
-
84888303259
-
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth
-
Garapaty-Rao, S., et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20, 1329-1339 (2013).
-
(2013)
Chem. Biol.
, vol.20
, pp. 1329-1339
-
-
Garapaty-Rao, S.1
-
82
-
-
84898034702
-
Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2
-
Nasveschuk, C. G., et al. Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2. ACS Med. Chem. Lett. 5, 378-383 (2014).
-
(2014)
ACS Med. Chem. Lett.
, vol.5
, pp. 378-383
-
-
Nasveschuk, C.G.1
-
83
-
-
84879750981
-
An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1
-
Konze, K. D., et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
-
(2013)
ACS Chem. Biol.
, vol.8
, pp. 1324-1334
-
-
Konze, K.D.1
-
84
-
-
84877324084
-
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
-
Knutson, S. K., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922-7927 (2013).
-
(2013)
Proc. Natl Acad. Sci. USA
, vol.110
, pp. 7922-7927
-
-
Knutson, S.K.1
-
85
-
-
84871248432
-
Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2
-
Verma, S. K., et al. Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3, 1091-1096 (2012).
-
(2012)
ACS Med. Chem. Lett.
, vol.3
, pp. 1091-1096
-
-
Verma, S.K.1
-
86
-
-
84921318899
-
Selective inhibition of EZH2 by EPZ 6438 leads to potent antitumor activity in EZH2 mutant non-Hodgkin lymphoma
-
Knutson, S. K., et al. Selective inhibition of EZH2 by EPZ 6438 leads to potent antitumor activity in EZH2 mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842-854 (2014).
-
(2014)
Mol. Cancer Ther.
, vol.13
, pp. 842-854
-
-
Knutson, S.K.1
-
87
-
-
84875715709
-
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells
-
Alimova, I., et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol. 15, 149-160 (2013).
-
(2013)
Neuro Oncol.
, vol.15
, pp. 149-160
-
-
Alimova, I.1
-
88
-
-
84874106911
-
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL AF9;Nras(G12D) acute myeloid leukemia
-
Shi, J., et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL AF9;Nras(G12D) acute myeloid leukemia. Oncogene 32, 930-938 (2013).
-
(2013)
Oncogene
, vol.32
, pp. 930-938
-
-
Shi, J.1
-
89
-
-
84859475727
-
Polycomb repressive complex 2 is required for MLL AF9 leukemia
-
Neff, T., et al. Polycomb repressive complex 2 is required for MLL AF9 leukemia. Proc. Natl Acad. Sci. USA 109, 5028-5033 (2012).
-
(2012)
Proc. Natl Acad. Sci. USA
, vol.109
, pp. 5028-5033
-
-
Neff, T.1
-
90
-
-
84939270225
-
Targeting EZH2 and PRC2 dependence as novel anticancer therapy
-
Xu, B., Konze, K. D., Jin, J., & Wang, G. G. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp. Hematol. 43, 698-712 (2015).
-
(2015)
Exp. Hematol.
, vol.43
, pp. 698-712
-
-
Xu, B.1
Konze, K.D.2
Jin, J.3
Wang, G.G.4
-
91
-
-
84945186017
-
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
-
aac4383
-
Jiao, L., & Liu, X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350, aac4383 (2015).
-
(2015)
Science
, pp. 350
-
-
Jiao, L.1
Liu, X.2
-
92
-
-
0035854372
-
State of the arg: Protein methylation at arginine comes of age
-
McBride, A. E., & Silver, P. A. State of the arg: protein methylation at arginine comes of age. Cell 106, 5-8 (2001).
-
(2001)
Cell
, vol.106
, pp. 5-8
-
-
McBride, A.E.1
Silver, P.A.2
-
93
-
-
84871712509
-
Protein arginine methyltransferases and cancer
-
Yang, Y., & Bedford, M. T. Protein arginine methyltransferases and cancer. Nat. Rev. Cancer 13, 37-50 (2013).
-
(2013)
Nat. Rev. Cancer
, vol.13
, pp. 37-50
-
-
Yang, Y.1
Bedford, M.T.2
-
94
-
-
84948410742
-
The dual epigenetic role of PRMT5 in acute myeloid leukemia: Gene activation and repression via histone arginine methylation
-
Tarighat, S. S., et al. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia 30, 789-799 (2016).
-
(2016)
Leukemia
, vol.30
, pp. 789-799
-
-
Tarighat, S.S.1
-
95
-
-
84890288945
-
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing
-
Chung, J., et al. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. J. Biol. Chem. 288, 35534-35547 (2013).
-
(2013)
J. Biol. Chem.
, vol.288
, pp. 35534-35547
-
-
Chung, J.1
-
96
-
-
84960916279
-
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
-
Kryukov, G. V., et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214-1218 (2016).
-
(2016)
Science
, vol.351
, pp. 1214-1218
-
-
Kryukov, G.V.1
-
97
-
-
84927747737
-
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B cell transformation
-
Alinari, L., et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B cell transformation. Blood 125, 2530-2543 (2015).
-
(2015)
Blood
, vol.125
, pp. 2530-2543
-
-
Alinari, L.1
-
98
-
-
84937397052
-
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
-
Chan-Penebre, E., et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 11, 432-437 (2015).
-
(2015)
Nat. Chem. Biol.
, vol.11
, pp. 432-437
-
-
Chan-Penebre, E.1
-
99
-
-
84935871823
-
Aryl pyrazoles as potent inhibitors of arginine methyltransferases: Identification of the first PRMT6 tool compound
-
Mitchell, L. H., et al. Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound. ACS Med. Chem. Lett. 6, 655-659 (2015).
-
(2015)
ACS Med. Chem. Lett.
, vol.6
, pp. 655-659
-
-
Mitchell, L.H.1
-
100
-
-
84927720612
-
A potent, selective and cell-Active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3)
-
Kaniskan, H. U., et al. A potent, selective and cell-Active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew. Chem. Int. Ed. 54, 5166-5170 (2015).
-
(2015)
Angew. Chem. Int. Ed.
, vol.54
, pp. 5166-5170
-
-
Kaniskan, H.U.1
-
101
-
-
84961820776
-
A potent, selective, and cell-Active inhibitor of human type i protein arginine methyltransferases
-
Eram, M. S., et al. A potent, selective, and cell-Active inhibitor of human type I protein arginine methyltransferases. ACS Chem. Biol. 11, 772-781 (2016).
-
(2016)
ACS Chem. Biol.
, vol.11
, pp. 772-781
-
-
Eram, M.S.1
-
102
-
-
11144332565
-
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
-
Shi, Y., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953 (2004).
-
(2004)
Cell
, vol.119
, pp. 941-953
-
-
Shi, Y.1
-
103
-
-
24144462170
-
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
-
Metzger, E., et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436-439 (2005).
-
(2005)
Nature
, vol.437
, pp. 436-439
-
-
Metzger, E.1
-
104
-
-
84880719085
-
The histone LSD1 demethylase in stemness and cancer transcription programs
-
Amente, S., Lania, L., & Majello, B. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim. Biophys. Acta 1829, 981-986 (2013).
-
(2013)
Biochim. Biophys. Acta
, vol.1829
, pp. 981-986
-
-
Amente, S.1
Lania, L.2
Majello, B.3
-
105
-
-
0034282790
-
Identification of a novel gene, GASC1, within an amplicon at 9p23 24 frequently detected in esophageal cancer cell lines
-
Yang, Z. Q., et al. Identification of a novel gene, GASC1, within an amplicon at 9p23 24 frequently detected in esophageal cancer cell lines. Cancer Res. 60, 4735-4739 (2000).
-
(2000)
Cancer Res.
, vol.60
, pp. 4735-4739
-
-
Yang, Z.Q.1
-
106
-
-
0035909531
-
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31
-
Hu, Z., et al. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 20, 6946-6954 (2001).
-
(2001)
Oncogene
, vol.20
, pp. 6946-6954
-
-
Hu, Z.1
-
107
-
-
33646138230
-
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor
-
Yamane, K., et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125, 483-495 (2006).
-
(2006)
Cell
, vol.125
, pp. 483-495
-
-
Yamane, K.1
-
108
-
-
33847392500
-
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
-
Wissmann, M., et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9, 347-353 (2007).
-
(2007)
Nat. Cell Biol.
, vol.9
, pp. 347-353
-
-
Wissmann, M.1
-
109
-
-
33745187327
-
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications
-
Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G., & Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13, 563-567 (2006).
-
(2006)
Chem. Biol.
, vol.13
, pp. 563-567
-
-
Lee, M.G.1
Wynder, C.2
Schmidt, D.M.3
McCafferty, D.G.4
Shiekhattar, R.5
-
110
-
-
34147173308
-
Trans 2 phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1
-
Schmidt, D. M., & McCafferty, D. G. trans 2 phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46, 4408-4416 (2007).
-
(2007)
Biochemistry
, vol.46
, pp. 4408-4416
-
-
Schmidt, D.M.1
McCafferty, D.G.2
-
111
-
-
34447338875
-
Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans 2 phenylcyclopropylamine
-
Yang, M., et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans 2 phenylcyclopropylamine. Biochemistry 46, 8058-8065 (2007).
-
(2007)
Biochemistry
, vol.46
, pp. 8058-8065
-
-
Yang, M.1
-
112
-
-
72249117352
-
Identification of cell-Active lysine specific demethylase 1 selective inhibitors
-
Ueda, R., et al. Identification of cell-Active lysine specific demethylase 1 selective inhibitors. J. Am. Chem. Soc.131, 17536-17537 (2009).
-
(2009)
J. Am. Chem. Soc.
, vol.131
, pp. 17536-17537
-
-
Ueda, R.1
-
113
-
-
77952355653
-
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2
-
Binda, C., et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132, 6827-6833 (2010).
-
(2010)
J. Am. Chem. Soc.
, vol.132
, pp. 6827-6833
-
-
Binda, C.1
-
114
-
-
77955025931
-
Structurally designed trans 2 phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1
-
Mimasu, S., et al. Structurally designed trans 2 phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49, 6494-6503 (2010).
-
(2010)
Biochemistry
, vol.49
, pp. 6494-6503
-
-
Mimasu, S.1
-
115
-
-
84859837026
-
The histone demethylase KDM1A sustains the oncogenic potential of MLL AF9 leukemia stem cells
-
Harris, W. J., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012).
-
(2012)
Cancer Cell
, vol.21
, pp. 473-487
-
-
Harris, W.J.1
-
116
-
-
84874598620
-
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency
-
Liang, Y., et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio 4, e00558 12 (2013).
-
(2013)
MBio
, vol.4
, pp. e0055812
-
-
Liang, Y.1
-
117
-
-
84937429405
-
A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC
-
Mohammad, H. P., et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28, 57-69 (2015).
-
(2015)
Cancer Cell
, vol.28
, pp. 57-69
-
-
Mohammad, H.P.1
-
118
-
-
84862777766
-
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-Trans-retinoic acid differentiation pathway in acute myeloid leukemia
-
Schenk, T., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-Trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605-611 (2012).
-
(2012)
Nat. Med.
, vol.18
, pp. 605-611
-
-
Schenk, T.1
-
119
-
-
84926475466
-
Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date
-
Mould, D. P., McGonagle, A. E., Wiseman, D. H., Williams, E. L., & Jordan, A. M. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med. Res. Rev. 35, 586-618 (2015).
-
(2015)
Med. Res. Rev.
, vol.35
, pp. 586-618
-
-
Mould, D.P.1
McGonagle, A.E.2
Wiseman, D.H.3
Williams, E.L.4
Jordan, A.M.5
-
120
-
-
84924423842
-
Novel anti-Tumor activity of targeted LSD1 inhibition by GSK2879552
-
Mohammad, H., et al. Novel anti-Tumor activity of targeted LSD1 inhibition by GSK2879552. Eur. J. Cancer 50, 72 (2014).
-
(2014)
Eur. J. Cancer
, vol.50
, pp. 72
-
-
Mohammad, H.1
-
121
-
-
36249005491
-
Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma
-
Smith, E. H., Janknecht, R., & Maher, L. J. III. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet. 16, 3136-3148 (2007).
-
(2007)
Hum. Mol. Genet.
, vol.16
, pp. 3136-3148
-
-
Smith, E.H.1
Janknecht, R.2
Maher, L.J.3
-
122
-
-
56749151276
-
Inhibitor scaffolds for 2 oxoglutarate-dependent histone lysine demethylases
-
Rose, N. R., et al. Inhibitor scaffolds for 2 oxoglutarate-dependent histone lysine demethylases. J. Med. Chem. 51, 7053-7056 (2008).
-
(2008)
J. Med. Chem.
, vol.51
, pp. 7053-7056
-
-
Rose, N.R.1
-
123
-
-
77649224314
-
Selective inhibitors of the JMJD2 histone demethylases: Combined nondenaturing mass spectrometric screening and crystallographic approaches
-
Rose, N. R., et al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 53, 1810-1818 (2010).
-
(2010)
J. Med. Chem.
, vol.53
, pp. 1810-1818
-
-
Rose, N.R.1
-
124
-
-
70350315800
-
Inhibition of the histone lysine demethylase JMJD2A by ejection of structural Zn(II)
-
Sekirnik, R., et al. Inhibition of the histone lysine demethylase JMJD2A by ejection of structural Zn(II). Chem. Commun. (Camb.) 42, 6376-6378 (2009).
-
(2009)
Chem. Commun. (Camb.)
, vol.42
, pp. 6376-6378
-
-
Sekirnik, R.1
-
125
-
-
33646061354
-
A mechanism-based inactivator for histone demethylase LSD1
-
Culhane, J. C., et al. A mechanism-based inactivator for histone demethylase LSD1. J. Am. Chem. Soc. 128, 4536-4537 (2006).
-
(2006)
J. Am. Chem. Soc.
, vol.128
, pp. 4536-4537
-
-
Culhane, J.C.1
-
126
-
-
65349129552
-
Synthesis and activity of N oxalylglycine and its derivatives as Jumonji C domain-containing histone lysine demethylase inhibitors
-
Hamada, S., et al. Synthesis and activity of N oxalylglycine and its derivatives as Jumonji C domain-containing histone lysine demethylase inhibitors. Bioorg. Med. Chem. Lett. 19, 2852-2855 (2009).
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 2852-2855
-
-
Hamada, S.1
-
127
-
-
78649528262
-
Quantitative high-Throughput screening identifies 8 hydroxyquinolines as cell-Active histone demethylase inhibitors
-
King, O. N., et al. Quantitative high-Throughput screening identifies 8 hydroxyquinolines as cell-Active histone demethylase inhibitors. PLoS ONE 5, e15535 (2010).
-
(2010)
PLoS ONE
, vol.5
, pp. e15535
-
-
King, O.N.1
-
128
-
-
78650107087
-
Inhibition of the histone demethylase JMJD2E by 3 substituted pyridine 2, 4 dicarboxylates
-
Thalhammer, A., et al. Inhibition of the histone demethylase JMJD2E by 3 substituted pyridine 2, 4 dicarboxylates. Org. Biomol. Chem. 9, 127-135 (2011).
-
(2011)
Org. Biomol. Chem.
, vol.9
, pp. 127-135
-
-
Thalhammer, A.1
-
129
-
-
79959204866
-
A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases
-
Luo, X., et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J. Am. Chem. Soc.133, 9451-9456 (2011).
-
(2011)
J. Am. Chem. Soc.
, vol.133
, pp. 9451-9456
-
-
Luo, X.1
-
130
-
-
84865120905
-
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
-
Kruidenier, L., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012).
-
(2012)
Nature
, vol.488
, pp. 404-408
-
-
Kruidenier, L.1
-
131
-
-
84907526739
-
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
-
Ntziachristos, P., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014).
-
(2014)
Nature
, vol.514
, pp. 513-517
-
-
Ntziachristos, P.1
-
132
-
-
84961291627
-
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
-
Hashizume, R., et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20, 1394-1396 (2014).
-
(2014)
Nat. Med.
, vol.20
, pp. 1394-1396
-
-
Hashizume, R.1
-
133
-
-
84908029332
-
Inhibition of demethylases by GSK J1/J4
-
Heinemann, B., et al. Inhibition of demethylases by GSK J1/J4. Nature 514, E1-E2 (2014).
-
(2014)
Nature
, vol.514
, pp. E1-E2
-
-
Heinemann, B.1
-
134
-
-
35848961668
-
How chromatin-binding modules interpret histone modifications: Lessons from professional pocket pickers
-
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025-1040 (2007).
-
(2007)
Nat. Struct. Mol. Biol.
, vol.14
, pp. 1025-1040
-
-
Taverna, S.D.1
Li, H.2
Ruthenburg, A.J.3
Allis, C.D.4
Patel, D.J.5
-
135
-
-
67349266612
-
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger
-
Wang, G. G., et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459, 847-851 (2009).
-
(2009)
Nature
, vol.459
, pp. 847-851
-
-
Wang, G.G.1
-
136
-
-
84874116695
-
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain
-
James, L. I., et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat. Chem. Biol. 9, 184-191 (2013).
-
(2013)
Nat. Chem. Biol.
, vol.9
, pp. 184-191
-
-
James, L.I.1
-
137
-
-
84884993346
-
Small-molecule ligands of methyl-lysine binding proteins: Optimization of selectivity for L3MBTL3
-
James, L. I., et al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J. Med. Chem. 56, 7358-7371 (2013).
-
(2013)
J. Med. Chem.
, vol.56
, pp. 7358-7371
-
-
James, L.I.1
-
138
-
-
84958983631
-
Selective inhibition of CBX6: A methyllysine reader protein in the Polycomb family
-
Milosevich, N., et al. Selective inhibition of CBX6: a methyllysine reader protein in the Polycomb family. ACS Med. Chem. Lett. 7, 139-144 (2016).
-
(2016)
ACS Med. Chem. Lett.
, vol.7
, pp. 139-144
-
-
Milosevich, N.1
-
139
-
-
84955558290
-
A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1
-
Stuckey, J. I., et al. A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nat. Chem. Biol. 12, 180-187 (2016).
-
(2016)
Nat. Chem. Biol.
, vol.12
, pp. 180-187
-
-
Stuckey, J.I.1
-
140
-
-
68949212379
-
Lysine acetylation targets protein complexes and co regulates major cellular functions
-
Choudhary, C., et al. Lysine acetylation targets protein complexes and co regulates major cellular functions. Science 325, 834-840 (2009).
-
(2009)
Science
, vol.325
, pp. 834-840
-
-
Choudhary, C.1
-
141
-
-
0034912742
-
Histone acetyltransferases
-
Roth, S. Y., Denu, J. M., & Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120 (2001).
-
(2001)
Annu. Rev. Biochem.
, vol.70
, pp. 81-120
-
-
Roth, S.Y.1
Denu, J.M.2
Allis, C.D.3
-
142
-
-
84934282991
-
The role of histone acetyltransferases in normal and malignant hematopoiesis
-
Sun, X. J., Man, N., Tan, Y., Nimer, S. D., & Wang, L. The role of histone acetyltransferases in normal and malignant hematopoiesis. Front. Oncol. 5, 108 (2015).
-
(2015)
Front. Oncol.
, vol.5
, pp. 108
-
-
Sun, X.J.1
Man, N.2
Tan, Y.3
Nimer, S.D.4
Wang, L.5
-
143
-
-
77954204335
-
Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor
-
Bowers, E. M., et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471-482 (2010).
-
(2010)
Chem. Biol.
, vol.17
, pp. 471-482
-
-
Bowers, E.M.1
-
144
-
-
84962381628
-
Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality via apoptotic cell death due to abrogation of MYC expression
-
Ogiwara, H., et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality via apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 6, 430-445 (2015).
-
(2015)
Cancer Discov.
, vol.6
, pp. 430-445
-
-
Ogiwara, H.1
-
145
-
-
80051470522
-
The leukemogenicity of AML1 ETO is dependent on site-specific lysine acetylation
-
Wang, L., et al. The leukemogenicity of AML1 ETO is dependent on site-specific lysine acetylation. Science 333, 765-769 (2011).
-
(2011)
Science
, vol.333
, pp. 765-769
-
-
Wang, L.1
-
146
-
-
77956047888
-
Nitric oxide-mediated histone hyperacetylation in oral cancer: Target for a water-soluble HAT inhibitor
-
Arif, M., et al. Nitric oxide-mediated histone hyperacetylation in oral cancer: target for a water-soluble HAT inhibitor, CTK7A. Chem. Biol. 17, 903-913 (2010).
-
(2010)
CTK7A. Chem. Biol.
, vol.17
, pp. 903-913
-
-
Arif, M.1
-
147
-
-
84877642396
-
Small-molecule inhibitors of acetyltransferase p300 identified by high-Throughput screening are potent anticancer agents
-
Yang, H., et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-Throughput screening are potent anticancer agents. Mol. Cancer Ther. 12, 610-620 (2013).
-
(2013)
Mol. Cancer Ther.
, vol.12
, pp. 610-620
-
-
Yang, H.1
-
148
-
-
69949169110
-
Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin
-
Ravindra, K. C., et al. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J. Biol. Chem. 284, 24453-24464 (2009).
-
(2009)
J. Biol. Chem.
, vol.284
, pp. 24453-24464
-
-
Ravindra, K.C.1
-
149
-
-
84879756597
-
Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor
-
Modak, R., et al. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor. ACS Chem. Biol. 8, 1311-1323 (2013).
-
(2013)
ACS Chem. Biol.
, vol.8
, pp. 1311-1323
-
-
Modak, R.1
-
150
-
-
84979496867
-
Salicylate diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
-
Shirakawa, K., et al. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. eLife 5, e11156 (2016).
-
(2016)
ELife
, vol.5
, pp. e11156
-
-
Shirakawa, K.1
-
151
-
-
39149109887
-
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
-
Liu, X., et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846-850 (2008).
-
(2008)
Nature
, vol.451
, pp. 846-850
-
-
Liu, X.1
-
152
-
-
84883743725
-
Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
-
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E., & Panne, D. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat. Struct. Mol. Biol. 20, 1040-1046 (2013).
-
(2013)
Nat. Struct. Mol. Biol.
, vol.20
, pp. 1040-1046
-
-
Delvecchio, M.1
Gaucher, J.2
Aguilar-Gurrieri, C.3
Ortega, E.4
Panne, D.5
-
153
-
-
33748451151
-
Anticancer activities of histone deacetylase inhibitors
-
Bolden, J. E., Peart, M. J., & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
-
(2006)
Nat. Rev. Drug Discov.
, vol.5
, pp. 769-784
-
-
Bolden, J.E.1
Peart, M.J.2
Johnstone, R.W.3
-
154
-
-
0035961036
-
Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin
-
Sternson, S. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 3, 4239-4242 (2001).
-
(2001)
Org. Lett.
, vol.3
, pp. 4239-4242
-
-
Sternson, S.M.1
Wong, J.C.2
Grozinger, C.M.3
Schreiber, S.L.4
-
155
-
-
1842578986
-
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
-
Gregoretti, I. V., Lee, Y. M., & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31 (2004).
-
(2004)
J. Mol. Biol.
, vol.338
, pp. 17-31
-
-
Gregoretti, I.V.1
Lee, Y.M.2
Goodson, H.V.3
-
156
-
-
77249087051
-
Chemical phylogenetics of histone deacetylases
-
Bradner, J. E., et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6, 238-243 (2010).
-
(2010)
Nat. Chem. Biol.
, vol.6
, pp. 238-243
-
-
Bradner, J.E.1
-
157
-
-
79952396960
-
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
-
Bantscheff, M., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
-
(2011)
Nat. Biotechnol.
, vol.29
, pp. 255-265
-
-
Bantscheff, M.1
-
158
-
-
0038274087
-
Structural biasing elements for in cell histone deacetylase paralog selectivity
-
Wong, J. C., Hong, R., & Schreiber, S. L. Structural biasing elements for in cell histone deacetylase paralog selectivity. J. Am. Chem. Soc. 125, 5586-5587 (2003).
-
(2003)
J. Am. Chem. Soc.
, vol.125
, pp. 5586-5587
-
-
Wong, J.C.1
Hong, R.2
Schreiber, S.L.3
-
159
-
-
0000032126
-
Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
-
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95, 3356-3361 (1998).
-
(1998)
Proc. Natl Acad. Sci. USA
, vol.95
, pp. 3356-3361
-
-
Kwon, H.J.1
Owa, T.2
Hassig, C.A.3
Shimada, J.4
Schreiber, S.L.5
-
160
-
-
49849106385
-
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
-
Hassig, C. A., et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7, 1054-1065 (2008).
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 1054-1065
-
-
Hassig, C.A.1
-
161
-
-
84865171888
-
Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo
-
Huang, H. L., et al. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS ONE 7, e43645 (2012).
-
(2012)
PLoS ONE
, vol.7
, pp. e43645
-
-
Huang, H.L.1
-
162
-
-
0017284850
-
A new antifungal antibiotic, trichostatin
-
Tsuji, N., Kobayashi, M., Nagashima, K., Wakisaka, Y., & Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. 29, 1-6 (1976).
-
(1976)
J. Antibiot.
, vol.29
, pp. 1-6
-
-
Tsuji, N.1
Kobayashi, M.2
Nagashima, K.3
Wakisaka, Y.4
Koizumi, K.5
-
163
-
-
0026548820
-
Morphological reversion of sis-Transformed NIH3T3 cells by trichostatin A
-
Sugita, K., Koizumi, K., & Yoshida, H Morphological Reversion of Sis-Transformed NIH3T3 Cells by Trichostatin A. Cancer Res. 52, 168-172 (1992).
-
(1992)
Cancer Res.
, vol.52
, pp. 168-172
-
-
Sugita, K.1
Koizumi, K.2
Yoshida, H.3
-
164
-
-
33847358736
-
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
-
Avila, A. M., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659-671 (2007).
-
(2007)
J. Clin. Invest.
, vol.117
, pp. 659-671
-
-
Avila, A.M.1
-
165
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T cell lymphoma
-
Olsen, E. A., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T cell lymphoma. J. Clin. Oncol. 25, 3109-3115 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3109-3115
-
-
Olsen, E.A.1
-
166
-
-
84949024001
-
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
-
Matthews, G. M., et al. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126, 2392-2403 (2015).
-
(2015)
Blood
, vol.126
, pp. 2392-2403
-
-
Matthews, G.M.1
-
167
-
-
84895815366
-
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
-
Minami, J., et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 28, 680-689 (2014).
-
(2014)
Leukemia
, vol.28
, pp. 680-689
-
-
Minami, J.1
-
168
-
-
84880655164
-
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma
-
Wells, C. E., et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS ONE 8, e68915 (2013).
-
(2013)
PLoS ONE
, vol.8
, pp. e68915
-
-
Wells, C.E.1
-
169
-
-
18244383806
-
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
-
Göttlicher, M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
-
(2001)
EMBO J.
, vol.20
, pp. 6969-6978
-
-
Göttlicher, M.1
-
170
-
-
0017767153
-
N Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
-
Riggs, M. G., Whittaker, R. G., Neumann, J. R., & Ingram, V. M. n Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268, 462-464 (1977).
-
(1977)
Nature
, vol.268
, pp. 462-464
-
-
Riggs, M.G.1
Whittaker, R.G.2
Neumann, J.R.3
Ingram, V.M.4
-
171
-
-
79955701085
-
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome Preliminary results of a phase II trial
-
Candelaria, M., et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase II trial. Ann. Hematol. 90, 379-387 (2011).
-
(2011)
Ann. Hematol.
, vol.90
, pp. 379-387
-
-
Candelaria, M.1
-
172
-
-
84857522968
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy
-
Coiffier, B., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30, 631-636 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 631-636
-
-
Coiffier, B.1
-
173
-
-
0036735385
-
FK228 (depsipeptide) as a natural prodrug that inhibits class i histone deacetylases
-
Furumai, R., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921 (2002).
-
(2002)
Cancer Res.
, vol.62
, pp. 4916-4921
-
-
Furumai, R.1
-
174
-
-
77954879663
-
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T cell lymphoma
-
Whittaker, S. J., et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T cell lymphoma. J. Clin. Oncol. 28, 4485-4491 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 4485-4491
-
-
Whittaker, S.J.1
-
175
-
-
0027185184
-
Acetyldinaline: A new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia
-
El Beltagi, H. M., Martens, A. C. M., Lelieveld, P., Haroun, E. A., & Hagenbeek, A. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 53, 3008-3014 (1993).
-
(1993)
Cancer Res.
, vol.53
, pp. 3008-3014
-
-
El Beltagi, H.M.1
Martens, A.C.M.2
Lelieveld, P.3
Haroun, E.A.4
Hagenbeek, A.5
-
176
-
-
0033551152
-
A synthetic inhibitor of histone deacetylase, MS 27 275, with marked in vivo antitumor activity against human tumors
-
Saito, A., et al. A synthetic inhibitor of histone deacetylase, MS 27 275, with marked in vivo antitumor activity against human tumors Proc. Natl Acad. Sci. USA 96, 4592-4597 (1999).
-
(1999)
Proc Natl Acad. Sci. USA
, vol.96
, pp. 4592-4597
-
-
Saito, A.1
-
177
-
-
38749090156
-
Design and synthesis of 4-[(s triazin 2 ylamino)methyl]-N-(2 aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors
-
Paquin, I., et al. Design and synthesis of 4-[(s triazin 2 ylamino)methyl]-N-(2 aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 18, 1067-1071 (2008).
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 1067-1071
-
-
Paquin, I.1
-
178
-
-
58149089923
-
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class i histone deacetylases
-
Chou, C. J., Herman, D., & Gottesfeld, J. M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 283, 35402-35409 (2008).
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 35402-35409
-
-
Chou, C.J.1
Herman, D.2
Gottesfeld, J.M.3
-
179
-
-
38749136234
-
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/ HDAC2 inhibitors (SHI 1:2)
-
Methot, J. L., et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/ HDAC2 inhibitors (SHI 1:2). Bioorg. Med. Chem. Lett. 18, 973-978 (2008).
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 973-978
-
-
Methot, J.L.1
-
180
-
-
84863194158
-
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
-
Jayathilaka, N., et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 40, 5378-5388 (2012).
-
(2012)
Nucleic Acids Res.
, vol.40
, pp. 5378-5388
-
-
Jayathilaka, N.1
-
181
-
-
71049156256
-
Identification of novel, selective, and stable inhibitors of class II histone deacetylases Validation studies of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy
-
Ontoria, J. M., et al. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J. Med. Chem. 52, 6782-6783 (2009).
-
(2009)
J. Med. Chem.
, vol.52
, pp. 6782-6783
-
-
Ontoria, J.M.1
-
182
-
-
84879092346
-
Selective class IIa histone deacetylase inhibition via a non-chelating zinc-binding group
-
Lobera, M., et al. Selective class IIa histone deacetylase inhibition via a non-chelating zinc-binding group. Nat. Chem. Biol. 9, 319-325 (2013).
-
(2013)
Nat. Chem. Biol.
, vol.9
, pp. 319-325
-
-
Lobera, M.1
-
183
-
-
20944435415
-
Class II (IIa)-selective histone deacetylase inhibitors. 1 Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxamides
-
Mai, A., et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxamides. J. Med. Chem. 48, 3344-3353 (2005).
-
(2005)
J. Med. Chem.
, vol.48
, pp. 3344-3353
-
-
Mai, A.1
-
184
-
-
84942372058
-
The multifaceted functions of sirtuins in cancer
-
Chalkiadaki, A., & Guarente, L. The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15, 608-624 (2015).
-
(2015)
Nat. Rev. Cancer
, vol.15
, pp. 608-624
-
-
Chalkiadaki, A.1
Guarente, L.2
-
185
-
-
53149137486
-
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice
-
Wang, R. H., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14, 312-323 (2008).
-
(2008)
Cancer Cell
, vol.14
, pp. 312-323
-
-
Wang, R.H.1
-
186
-
-
84898011296
-
Sorting out functions of sirtuins in cancer
-
Roth, M., & Chen, W. Y. Sorting out functions of sirtuins in cancer. Oncogene 33, 1609-1620 (2014).
-
(2014)
Oncogene
, vol.33
, pp. 1609-1620
-
-
Roth, M.1
Chen, W.Y.2
-
187
-
-
84867702707
-
Sirtuin activators and inhibitors
-
Villalba, J. M., & Alcain, F. J. Sirtuin activators and inhibitors. BioFactors 38, 349-359 (2012).
-
(2012)
BioFactors
, vol.38
, pp. 349-359
-
-
Villalba, J.M.1
Alcain, F.J.2
-
188
-
-
0141719702
-
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
-
Howitz, K. T., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
-
(2003)
Nature
, vol.425
, pp. 191-196
-
-
Howitz, K.T.1
-
189
-
-
36749087548
-
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
-
Milne, J. C., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).
-
(2007)
Nature
, vol.450
, pp. 712-716
-
-
Milne, J.C.1
-
190
-
-
81155148158
-
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells
-
Chauhan, D., et al. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br. J. Haematol. 155, 588-598 (2011).
-
(2011)
Br. J. Haematol.
, vol.155
, pp. 588-598
-
-
Chauhan, D.1
-
191
-
-
84926628784
-
DOT1L inhibits SIRT1 mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
-
Chen, C. W., et al. DOT1L inhibits SIRT1 mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21, 335-343 (2015).
-
(2015)
Nat. Med.
, vol.21
, pp. 335-343
-
-
Chen, C.W.1
-
192
-
-
0037160097
-
Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1
-
Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099-45107 (2002).
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 45099-45107
-
-
Bitterman, K.J.1
Anderson, R.M.2
Cohen, H.Y.3
Latorre-Esteves, M.4
Sinclair, D.A.5
-
193
-
-
37349110743
-
Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide
-
Smith, B. C., & Denu, J. M. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry 46, 14478-14486 (2007).
-
(2007)
Biochemistry
, vol.46
, pp. 14478-14486
-
-
Smith, B.C.1
Denu, J.M.2
-
194
-
-
28144438533
-
Design, syn thesis, and biological evaluation of sirtinol analogues as class III histone/ protein deacetylase (Sirtuin) inhibitors
-
Mai, A., et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/ protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48, 7789-7795 (2005).
-
(2005)
J. Med. Chem.
, vol.48
, pp. 7789-7795
-
-
Mai, A.1
-
195
-
-
0035914304
-
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening
-
Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D., & Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276, 38837-38843 (2001).
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 38837-38843
-
-
Grozinger, C.M.1
Chao, E.D.2
Blackwell, H.E.3
Moazed, D.4
Schreiber, S.L.5
-
196
-
-
9744284968
-
An in silico approach to discovering novel inhibitors of human sirtuin type 2
-
Tervo, A. J., et al. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J. Med. Chem. 47, 6292-6298 (2004).
-
(2004)
J. Med. Chem.
, vol.47
, pp. 6292-6298
-
-
Tervo, A.J.1
-
197
-
-
53649086367
-
Mechanisms and molecular probes of sirtuins
-
Smith, B. C., Hallows, W. C., & Denu, J. M. Mechanisms and molecular probes of sirtuins. Chem. Biol. 15, 1002-1013 (2008).
-
(2008)
Chem. Biol.
, vol.15
, pp. 1002-1013
-
-
Smith, B.C.1
Hallows, W.C.2
Denu, J.M.3
-
198
-
-
84881613507
-
Pleiotropic effects of the sirtuin inhibitor sirtinol involves concentration-dependent modulation of multiple nuclear receptor-mediated pathways in androgen-responsive prostate cancer cell LNCaP
-
Wang, T. T., Schoene, N. W., Kim, E. K., & Kim, Y. S. Pleiotropic effects of the sirtuin inhibitor sirtinol involves concentration-dependent modulation of multiple nuclear receptor-mediated pathways in androgen-responsive prostate cancer cell LNCaP. Mol. Carcinog. 52, 676-685 (2013).
-
(2013)
Mol. Carcinog.
, vol.52
, pp. 676-685
-
-
Wang, T.T.1
Schoene, N.W.2
Kim, E.K.3
Kim, Y.S.4
-
199
-
-
0035910031
-
Identification of a small molecule inhibitor of Sir2p
-
Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., & Simon, J. A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl Acad. Sci. USA 98, 15113-15118 (2001).
-
(2001)
Proc. Natl Acad. Sci. USA
, vol.98
, pp. 15113-15118
-
-
Bedalov, A.1
Gatbonton, T.2
Irvine, W.P.3
Gottschling, D.E.4
Simon, J.A.5
-
200
-
-
33646254136
-
Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
-
Heltweg, B., et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368-4377 (2006).
-
(2006)
Cancer Res.
, vol.66
, pp. 4368-4377
-
-
Heltweg, B.1
-
201
-
-
84899500104
-
Development of pyrazolone and isoxazol 5 one cambinol analogues as sirtuin inhibitors
-
Mahajan, S. S., et al. Development of pyrazolone and isoxazol 5 one cambinol analogues as sirtuin inhibitors. J. Med. Chem. 57, 3283-3294 (2014).
-
(2014)
J. Med. Chem.
, vol.57
, pp. 3283-3294
-
-
Mahajan, S.S.1
-
202
-
-
42949114938
-
Discovery. in vivo activity, and mechanism of action of a small-molecule p53 activator
-
Lain, S., et al. Discovery. in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454-463 (2008).
-
(2008)
Cancer Cell
, vol.13
, pp. 454-463
-
-
Lain, S.1
-
203
-
-
84863011183
-
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib
-
Li, L., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281 (2012).
-
(2012)
Cancer Cell
, vol.21
, pp. 266-281
-
-
Li, L.1
-
204
-
-
84876473075
-
Tenovin D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53 independent manner
-
McCarthy, A. R., et al. Tenovin D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53 independent manner. Mol. Cancer Ther. 12, 352-360 (2013).
-
(2013)
Mol. Cancer Ther.
, vol.12
, pp. 352-360
-
-
McCarthy, A.R.1
-
205
-
-
84888375767
-
The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B cell lymphoma
-
Newbold, A., Salmon, J. M., Martin, B. P., Stanley, K., & Johnstone, R. W. The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B cell lymphoma. Oncogene 33, 5415-5423 (2014).
-
(2014)
Oncogene
, vol.33
, pp. 5415-5423
-
-
Newbold, A.1
Salmon, J.M.2
Martin, B.P.3
Stanley, K.4
Johnstone, R.W.5
-
206
-
-
35548936745
-
Structure-Activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins)
-
Trapp, J., et al. Structure-Activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem 2, 1419-1431 (2007).
-
(2007)
ChemMedChem
, vol.2
, pp. 1419-1431
-
-
Trapp, J.1
-
207
-
-
58149392612
-
Suramin: Clinical uses and structure-Activity relationships
-
McGeary, R. P., Bennett, A. J., Tran, Q. B., Cosgrove, K. L., & Ross, B. P. Suramin: clinical uses and structure-Activity relationships. Mini Rev. Med. Chem. 8, 1384-1394 (2008).
-
(2008)
Mini Rev. Med. Chem.
, vol.8
, pp. 1384-1394
-
-
McGeary, R.P.1
Bennett, A.J.2
Tran, Q.B.3
Cosgrove, K.L.4
Ross, B.P.5
-
208
-
-
0034128221
-
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
-
Small, E. J., et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J. Clin. Oncol. 18, 1440-1450 (2000).
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 1440-1450
-
-
Small, E.J.1
-
209
-
-
33645221885
-
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage
-
Solomon, J. M., et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26, 28-38 (2006).
-
(2006)
Mol. Cell. Biol.
, vol.26
, pp. 28-38
-
-
Solomon, J.M.1
-
210
-
-
34547599329
-
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson?s disease
-
Outeiro, T. F., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson?s disease. Science 317, 516-519 (2007).
-
(2007)
Science
, vol.317
, pp. 516-519
-
-
Outeiro, T.F.1
-
211
-
-
0033519641
-
Structure and ligand of a histone acetyltransferase bromodomain
-
Dhalluin, C., et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496 (1999).
-
(1999)
Nature
, vol.399
, pp. 491-496
-
-
Dhalluin, C.1
-
212
-
-
0034717183
-
Structure and function of a human TAFII250 double bromodomain module
-
Jacobson, R. H., Ladurner, A. G., King, D. S., & Tjian, R. Structure and function of a human TAFII250 double bromodomain module. Science 288, 1422-1425 (2000).
-
(2000)
Science
, vol.288
, pp. 1422-1425
-
-
Jacobson, R.H.1
Ladurner, A.G.2
King, D.S.3
Tjian, R.4
-
213
-
-
0041806599
-
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
-
Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., & Ozato, K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl Acad. Sci. USA 100, 8758-8763 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 8758-8763
-
-
Dey, A.1
Chitsaz, F.2
Abbasi, A.3
Misteli, T.4
Ozato, K.5
-
214
-
-
73949087197
-
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription
-
Dey, A., Nishiyama, A., Karpova, T., McNally, J., & Ozato, K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell 20, 4899-4909 (2009).
-
(2009)
Mol. Biol. Cell
, vol.20
, pp. 4899-4909
-
-
Dey, A.1
Nishiyama, A.2
Karpova, T.3
McNally, J.4
Ozato, K.5
-
215
-
-
80455122751
-
Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re activation
-
Zhao, R., Nakamura, T., Fu, Y., Lazar, Z., & Spector, D. L. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re activation. Nat. Cell Biol. 13, 1295-1304 (2011).
-
(2011)
Nat. Cell Biol.
, vol.13
, pp. 1295-1304
-
-
Zhao, R.1
Nakamura, T.2
Fu, Y.3
Lazar, Z.4
Spector, D.L.5
-
216
-
-
70349669271
-
Cooperative binding of two acetylation marks on a histone tail by a single bromodomain
-
Morinière, J., et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 664-668 (2009).
-
(2009)
Nature
, vol.461
, pp. 664-668
-
-
Morinière, J.1
-
217
-
-
84937639611
-
BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia
-
Roe, J. S., Mercan, F., Rivera, K., Pappin, D. J., & Vakoc, C. R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell 58, 1028-1039 (2015).
-
(2015)
Mol. Cell
, vol.58
, pp. 1028-1039
-
-
Roe, J.S.1
Mercan, F.2
Rivera, K.3
Pappin, D.J.4
Vakoc, C.R.5
-
218
-
-
41649120757
-
BRD-NUT oncoproteins: A family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells
-
French, C. A., et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27, 2237-2242 (2008).
-
(2008)
Oncogene
, vol.27
, pp. 2237-2242
-
-
French, C.A.1
-
219
-
-
78650847770
-
Selective inhibition of BET bromodomains
-
Filippakopoulos, P., et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
-
(2010)
Nature
, vol.468
, pp. 1067-1073
-
-
Filippakopoulos, P.1
-
220
-
-
0021949612
-
Alprazolam: Review of pharmacological, pharmacokinetic, and clinical data
-
VonVoigtlander, P. F., & Straw, R. N. Alprazolam: review of pharmacological, pharmacokinetic, and clinical data. Drug Dev. Res. 6, 1-12 (1985).
-
(1985)
Drug Dev. Res.
, vol.6
, pp. 1-12
-
-
Von Voigtlander, P.F.1
Straw, R.N.2
-
221
-
-
84857913614
-
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
-
Filippakopoulos, P., et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg. Med. Chem. 20, 1878-1886 (2012).
-
(2012)
Bioorg. Med. Chem.
, vol.20
, pp. 1878-1886
-
-
Filippakopoulos, P.1
-
222
-
-
84892164371
-
Genome-wide localization of small molecules
-
Anders, L., et al. Genome-wide localization of small molecules. Nat. Biotechnol. 32, 92-96 (2014).
-
(2014)
Nat. Biotechnol.
, vol.32
, pp. 92-96
-
-
Anders, L.1
-
223
-
-
80055000824
-
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
-
Zuber, J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
-
(2011)
Nature
, vol.478
, pp. 524-528
-
-
Zuber, J.1
-
224
-
-
80054984945
-
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
-
Dawson, M. A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
-
(2011)
Nature
, vol.478
, pp. 529-533
-
-
Dawson, M.A.1
-
225
-
-
23744467035
-
Recruitment of P TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4
-
Yang, Z., et al. Recruitment of P TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535-545 (2005).
-
(2005)
Mol. Cell
, vol.19
, pp. 535-545
-
-
Yang, Z.1
-
226
-
-
38549113034
-
Brd4 recruits P TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression
-
Yang, Z., He, N., & Zhou, Q. Brd4 recruits P TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28, 967-976 (2008).
-
(2008)
Mol. Cell. Biol.
, vol.28
, pp. 967-976
-
-
Yang, Z.1
He, N.2
Zhou, Q.3
-
227
-
-
77249119762
-
The landscape of somatic copy-number alteration across human cancers
-
Beroukhim, R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
-
(2010)
Nature
, vol.463
, pp. 899-905
-
-
Beroukhim, R.1
-
228
-
-
77951920690
-
C Myc regulates transcriptional pause release
-
Rahl, P. B., et al. c Myc regulates transcriptional pause release. Cell 141, 432-445 (2010).
-
(2010)
Cell
, vol.141
, pp. 432-445
-
-
Rahl, P.B.1
-
229
-
-
80052955256
-
BET bromodomain inhibition as a therapeutic strategy to target c Myc
-
Delmore, J. E., et al. BET bromodomain inhibition as a therapeutic strategy to target c Myc. Cell 146, 904-917 (2011).
-
(2011)
Cell
, vol.146
, pp. 904-917
-
-
Delmore, J.E.1
-
230
-
-
80053651202
-
Targeting MYC dependence in cancer by inhibiting BET bromodomains
-
Mertz, J. A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669-16674 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, pp. 16669-16674
-
-
Mertz, J.A.1
-
231
-
-
84867316537
-
BET bromodomain inhibition targets both c Myc and IL7R in high-risk acute lymphoblastic leukemia
-
Ott, C. J., et al. BET bromodomain inhibition targets both c Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843-2852 (2012).
-
(2012)
Blood
, vol.120
, pp. 2843-2852
-
-
Ott, C.J.1
-
232
-
-
84876222028
-
Selective inhibition of tumor oncogenes by disruption of super-enhancers
-
Lovén, J., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
-
(2013)
Cell
, vol.153
, pp. 320-334
-
-
Lovén, J.1
-
233
-
-
0001087931
-
Extreme instability of myc mRNA in normal and transformed human cells
-
Dani, C., et al. Extreme instability of myc mRNA in normal and transformed human cells. Proc. Natl Acad. Sci. USA 81, 7046-7050 (1984).
-
(1984)
Proc. Natl Acad. Sci. USA
, vol.81
, pp. 7046-7050
-
-
Dani, C.1
-
234
-
-
84891953718
-
Discovery and characterization of super-enhancer-Associated dependencies in diffuse large B cell lymphoma
-
Chapuy, B., et al. Discovery and characterization of super-enhancer-Associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013).
-
(2013)
Cancer Cell
, vol.24
, pp. 777-790
-
-
Chapuy, B.1
-
235
-
-
84899927814
-
Brd4 maintains constitutively active NF kappaB in cancer cells by binding to acetylated RelA
-
Zou, Z., et al. Brd4 maintains constitutively active NF kappaB in cancer cells by binding to acetylated RelA. Oncogene 33, 2395-2404 (2014).
-
(2014)
Oncogene
, vol.33
, pp. 2395-2404
-
-
Zou, Z.1
-
236
-
-
84931560527
-
Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4
-
Lu, J., et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015).
-
(2015)
Chem. Biol.
, vol.22
, pp. 755-763
-
-
Lu, J.1
-
237
-
-
79958078949
-
Discovery and characterization of small molecule inhibitors of the BET family bromodomains
-
Chung, C. W., et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827-3838 (2011).
-
(2011)
J. Med. Chem.
, vol.54
, pp. 3827-3838
-
-
Chung, C.W.1
-
238
-
-
80053924872
-
3, 5 Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands
-
Hewings, D. S., et al. 3, 5 Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 54, 6761-6770 (2011).
-
(2011)
J. Med. Chem.
, vol.54
, pp. 6761-6770
-
-
Hewings, D.S.1
-
239
-
-
79954552505
-
The super elongation complex (SEC) and MLL in development and disease
-
Smith, E., Lin, C., & Shilatifard, A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25, 661-672 (2011).
-
(2011)
Genes Dev.
, vol.25
, pp. 661-672
-
-
Smith, E.1
Lin, C.2
Shilatifard, A.3
-
240
-
-
77953246813
-
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis
-
Muntean, A. G., et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17, 609-621 (2010).
-
(2010)
Cancer Cell
, vol.17
, pp. 609-621
-
-
Muntean, A.G.1
-
241
-
-
84878565710
-
PFI 1, a highly selective protein interaction inhibitor, targeting BET bromodomains
-
Picaud, S., et al. PFI 1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 73, 3336-3346 (2013).
-
(2013)
Cancer Res.
, vol.73
, pp. 3336-3346
-
-
Picaud, S.1
-
242
-
-
84896611007
-
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
-
Ciceri, P., et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305-312 (2014).
-
(2014)
Nat. Chem. Biol.
, vol.10
, pp. 305-312
-
-
Ciceri, P.1
-
243
-
-
84961933254
-
Safety, tolerability, and preliminary activity of CUDC 907, a first in class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: An open-label, dose-escalation, phase 1 trial
-
Younes, A., et al. Safety, tolerability, and preliminary activity of CUDC 907, a first in class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 17, 622-631 (2016).
-
(2016)
Lancet Oncol.
, vol.17
, pp. 622-631
-
-
Younes, A.1
-
244
-
-
84964691616
-
IDH mutations in cancer and progress toward development of targeted therapeutics
-
Dang, L., Yen, K., & Attar, E. C. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol. 27, 599-608 (2016).
-
(2016)
Ann. Oncol.
, vol.27
, pp. 599-608
-
-
Dang, L.1
Yen, K.2
Attar, E.C.3
-
245
-
-
65349196261
-
Constrained (l-)-S adenosyl-l homocysteine (SAH) analogues as DNA methyltransferase inhibitors
-
Isakovic, L., et al. Constrained (l-)-S adenosyl-l homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg. Med. Chem. Lett. 19, 2742-2746 (2009).
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 2742-2746
-
-
Isakovic, L.1
-
246
-
-
0028151343
-
Toxicity of 5 aza 2? Deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
-
Jüttermann, R., Li, E., & Jaenisch, R. Toxicity of 5 aza 2? deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl Acad. Sci. USA 91, 11797-11801 (1994).
-
(1994)
Proc. Natl Acad. Sci. USA
, vol.91
, pp. 11797-11801
-
-
Jüttermann, R.1
Li, E.2
Jaenisch, R.3
-
247
-
-
0020582853
-
On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs
-
Santi, D. V., Garrett, C. E., & Barr, P. J. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33, 9-10 (1983).
-
(1983)
Cell
, vol.33
, pp. 9-10
-
-
Santi, D.V.1
Garrett, C.E.2
Barr, P.J.3
-
248
-
-
22144461094
-
Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy
-
Gowher, H., & Jeltsch, A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol. Ther. 3, 1062-1068 (2004).
-
(2004)
Cancer Biol. Ther.
, vol.3
, pp. 1062-1068
-
-
Gowher, H.1
Jeltsch, A.2
-
249
-
-
0014872738
-
Cytotoxicity and mode of action of 5 azacytidine on L1210 leukemia
-
Li, L. H., Olin, E. J., Buskirk, H. H., & Reineke, L. M. Cytotoxicity and mode of action of 5 azacytidine on L1210 leukemia. Cancer Res. 30, 2760-2769 (1970).
-
(1970)
Cancer Res.
, vol.30
, pp. 2760-2769
-
-
Li, L.H.1
Olin, E.J.2
Buskirk, H.H.3
Reineke, L.M.4
-
250
-
-
84861892178
-
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5 azacytidine activity in acute myeloid leukemia
-
Aimiuwu, J., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5 azacytidine activity in acute myeloid leukemia. Blood 119, 5229-5238 (2012).
-
(2012)
Blood
, vol.119
, pp. 5229-5238
-
-
Aimiuwu, J.1
-
251
-
-
70350234722
-
Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines
-
Schaefer, M., Hagemann, S., Hanna, K., & Lyko, F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 69, 8127-8132 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 8127-8132
-
-
Schaefer, M.1
Hagemann, S.2
Hanna, K.3
Lyko, F.4
-
252
-
-
33646071894
-
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
-
Kantarjian, H., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794-1803 (2006).
-
(2006)
Cancer
, vol.106
, pp. 1794-1803
-
-
Kantarjian, H.1
-
253
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
Fenaux, P., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223-232 (2009).
-
(2009)
Lancet Oncol.
, vol.10
, pp. 223-232
-
-
Fenaux, P.1
-
254
-
-
77952203695
-
S110, a 5 aza 2? Deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth
-
Chuang, J. C., et al. S110, a 5 aza 2? deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 9, 1443-1450 (2010).
-
(2010)
Mol. Cancer Ther.
, vol.9
, pp. 1443-1450
-
-
Chuang, J.C.1
-
255
-
-
84908247072
-
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
-
Bejar, R., et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124, 2705-2712 (2014).
-
(2014)
Blood
, vol.124
, pp. 2705-2712
-
-
Bejar, R.1
-
256
-
-
0022453948
-
Studies of mutagenicity and clastogenicity of 5 azacytidine in human lymphoblasts and Salmonella typhimurium
-
Call, K. M., Jensen, J. C., Liber, H. L., & Thilly, W. G. Studies of mutagenicity and clastogenicity of 5 azacytidine in human lymphoblasts and Salmonella typhimurium. Mutat. Res. 160, 249-257 (1986).
-
(1986)
Mutat. Res.
, vol.160
, pp. 249-257
-
-
Call, K.M.1
Jensen, J.C.2
Liber, H.L.3
Thilly, W.G.4
-
257
-
-
0023936754
-
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity
-
Cornacchia, E., et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140, 2197-2200 (1988).
-
(1988)
J. Immunol.
, vol.140
, pp. 2197-2200
-
-
Cornacchia, E.1
-
258
-
-
76449100936
-
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation
-
Kuck, D., Singh, N., Lyko, F., & Medina-Franco, J. L. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem. 18, 822-829 (2010).
-
(2010)
Bioorg. Med. Chem.
, vol.18
, pp. 822-829
-
-
Kuck, D.1
Singh, N.2
Lyko, F.3
Medina-Franco, J.L.4
-
259
-
-
31544439666
-
Discovery of two novel, small-molecule inhibitors of DNA methylation
-
Siedlecki, P., et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem. 49, 678-683 (2006).
-
(2006)
J. Med. Chem.
, vol.49
, pp. 678-683
-
-
Siedlecki, P.1
-
260
-
-
66249127951
-
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation
-
Datta, J., et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 69, 4277-4285 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 4277-4285
-
-
Datta, J.1
-
261
-
-
22244435605
-
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
-
Brueckner, B., et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 65, 6305-6311 (2005).
-
(2005)
Cancer Res.
, vol.65
, pp. 6305-6311
-
-
Brueckner, B.1
-
262
-
-
84856990498
-
Structure-based mechanistic insights into DNMT1 mediated maintenance DNA methylation
-
Song, J., Teplova, M., Ishibe-Murakami, S., & Patel, D. J. Structure-based mechanistic insights into DNMT1 mediated maintenance DNA methylation. Science 335, 709-712 (2012).
-
(2012)
Science
, vol.335
, pp. 709-712
-
-
Song, J.1
Teplova, M.2
Ishibe-Murakami, S.3
Patel, D.J.4
-
263
-
-
0019190864
-
Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus
-
Dubroff, L. M., & Reid, R. J. Jr. Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus. Science 208, 404-406 (1980).
-
(1980)
Science
, vol.208
, pp. 404-406
-
-
Dubroff, L.M.1
Reid, R.J.2
-
264
-
-
28844497663
-
Procainamide is a specific inhibitor of DNA methyltransferase 1
-
Lee, B. H., Yegnasubramanian, S., Lin, X., & Nelson, W. G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 280, 40749-40756 (2005).
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 40749-40756
-
-
Lee, B.H.1
Yegnasubramanian, S.2
Lin, X.3
Nelson, W.G.4
-
265
-
-
10744225448
-
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy
-
Segura-Pacheco, B., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 9, 1596-1603 (2003).
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 1596-1603
-
-
Segura-Pacheco, B.1
-
266
-
-
80053383964
-
Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A
-
Caulfield, T., & Medina-Franco, J. L. Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A. J. Struct. Biol. 176, 185-191 (2011).
-
(2011)
J. Struct. Biol.
, vol.176
, pp. 185-191
-
-
Caulfield, T.1
Medina-Franco, J.L.2
-
267
-
-
77956153243
-
The language of histone crosstalk
-
Lee, J. S., Smith, E., & Shilatifard, A. The language of histone crosstalk. Cell 142, 682-685 (2010).
-
(2010)
Cell
, vol.142
, pp. 682-685
-
-
Lee, J.S.1
Smith, E.2
Shilatifard, A.3
-
268
-
-
84879341188
-
A dual role for Hdac1: Oncosuppressor in tumorigenesis, oncogene in tumor maintenance
-
Santoro, F., et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121, 3459-3468 (2013).
-
(2013)
Blood
, vol.121
, pp. 3459-3468
-
-
Santoro, F.1
-
269
-
-
84877609321
-
Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c Myc collaborating genes and p53 function
-
Heideman, M. R., et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c Myc collaborating genes and p53 function. Blood 121, 2038-2050 (2013).
-
(2013)
Blood
, vol.121
, pp. 2038-2050
-
-
Heideman, M.R.1
-
270
-
-
0034234237
-
CBP/p300 in cell growth, transformation, and development
-
Goodman, R. H., & Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577 (2000).
-
(2000)
Genes Dev.
, vol.14
, pp. 1553-1577
-
-
Goodman, R.H.1
Smolik, S.2
-
271
-
-
0030797585
-
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C terminal domain
-
Gu, W., & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C terminal domain. Cell 90, 595-606 (1997).
-
(1997)
Cell
, vol.90
, pp. 595-606
-
-
Gu, W.1
Roeder, R.G.2
-
272
-
-
77949893772
-
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
-
Shiota, M., et al. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 70, 540-554 (2010).
-
(2010)
Prostate
, vol.70
, pp. 540-554
-
-
Shiota, M.1
-
273
-
-
34548312368
-
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response
-
Gorrini, C., et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448, 1063-1067 (2007).
-
(2007)
Nature
, vol.448
, pp. 1063-1067
-
-
Gorrini, C.1
-
274
-
-
84896711459
-
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-Analysis of individual patient data
-
Palumbo, A., et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-Analysis of individual patient data. Lancet Oncol. 15, 333-342 (2014).
-
(2014)
Lancet Oncol.
, vol.15
, pp. 333-342
-
-
Palumbo, A.1
-
275
-
-
84908265816
-
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
-
Falkenberg, K. J., & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673-691 (2014).
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, pp. 673-691
-
-
Falkenberg, K.J.1
Johnstone, R.W.2
-
276
-
-
84866183822
-
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
-
Deardorff, M. A., et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 489, 313-317 (2012).
-
(2012)
Nature
, vol.489
, pp. 313-317
-
-
Deardorff, M.A.1
-
277
-
-
84890080778
-
The up regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma
-
Wu, J., et al. The up regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig. Dis. Sci. 58, 3545-3553 (2013).
-
(2013)
Dig. Dis. Sci.
, vol.58
, pp. 3545-3553
-
-
Wu, J.1
-
278
-
-
77954831404
-
An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha
-
Wilson, B. J., Tremblay, A. M., Deblois, G., Sylvain-Drolet, G., & Giguère, V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol. Endocrinol. 24, 1349-1358 (2010).
-
(2010)
Mol. Endocrinol.
, vol.24
, pp. 1349-1358
-
-
Wilson, B.J.1
Tremblay, A.M.2
Deblois, G.3
Sylvain-Drolet, G.4
Giguère, V.5
-
279
-
-
43749109171
-
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI 34051 induces apoptosis in T cell lymphomas
-
Balasubramanian, S., et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI 34051 induces apoptosis in T cell lymphomas. Leukemia 22, 1026-1034 (2008).
-
(2008)
Leukemia
, vol.22
, pp. 1026-1034
-
-
Balasubramanian, S.1
-
280
-
-
84961291039
-
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation
-
Rettig, I., et al. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis. 6, e1657 (2015).
-
(2015)
Cell Death Dis.
, vol.6
, pp. e1657
-
-
Rettig, I.1
-
281
-
-
84873173538
-
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes
-
Li, Y., Shin, D., & Kwon, S. H. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 280, 775-793 (2013).
-
(2013)
FEBS J.
, vol.280
, pp. 775-793
-
-
Li, Y.1
Shin, D.2
Kwon, S.H.3
-
282
-
-
22844432021
-
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
-
Bali, P., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734 (2005).
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 26729-26734
-
-
Bali, P.1
-
283
-
-
0346020435
-
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
-
Kawaguchi, Y., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727-738 (2003).
-
(2003)
Cell
, vol.115
, pp. 727-738
-
-
Kawaguchi, Y.1
-
284
-
-
34548416641
-
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
-
Boyault, C., et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 21, 2172-2181 (2007).
-
(2007)
Genes Dev.
, vol.21
, pp. 2172-2181
-
-
Boyault, C.1
-
285
-
-
0344640906
-
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
-
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389-4394 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 4389-4394
-
-
Haggarty, S.J.1
Koeller, K.M.2
Wong, J.C.3
Grozinger, C.M.4
Schreiber, S.L.5
-
286
-
-
84858640254
-
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY 1215, in combination with bortezomib in multiple myeloma
-
Santo, L., et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY 1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579-2589 (2012).
-
(2012)
Blood
, vol.119
, pp. 2579-2589
-
-
Santo, L.1
-
287
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01684150 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
288
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02082977 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
289
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01897571 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
290
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02395601 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
291
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02273102 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
292
-
-
84984679985
-
-
ClinicalTrials.gov.
-
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02177812 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
293
-
-
85013674820
-
-
ClinicalTrialsRegister.eu
-
EU Clinical Trials Register. ClinicalTrialsRegister.eu https://www.clinicaltrialsregister.eu/ctr-search/ trial/2013-002447-29/ES (2013).
-
(2013)
EU Clinical Trials Register.
-
-
-
294
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01713582 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
295
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01949883 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
296
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02419417 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
297
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01587703 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
298
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02391480 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
299
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02308761 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
300
-
-
84984679985
-
-
ClinicalTrials.gov
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02468687 (2016).
-
(2016)
US National Library of Medicine.
-
-
-
301
-
-
84940562761
-
Belinostat in patients with relapsed or refractory peripheral T cell lymphoma: Results of the pivotal Phase II BELIEF (CLN 19) Study
-
O?Connor, O. A., et al. Belinostat in patients with relapsed or refractory peripheral T cell lymphoma: results of the pivotal Phase II BELIEF (CLN 19) Study. J. Clin. Oncol. 33, 2492-2499 (2015).
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 2492-2499
-
-
O'Connor, O.A.1
-
302
-
-
84908133944
-
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial
-
San-Miguel, J. F., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195-1206 (2014).
-
(2014)
Lancet Oncol.
, vol.15
, pp. 1195-1206
-
-
San-Miguel, J.F.1
|